Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer’s disease and stress disorders

Dorien Vandael¹,²,³ and Natalia V. Gounko¹,²,³

Abstract

Alzheimer’s disease is the most common cause of dementia and one of the most complex human neurodegenerative diseases. Numerous studies have demonstrated a critical role of the environment in the pathogenesis and pathophysiology of the disease, where daily life stress plays an important role. A lot of epigenetic studies have led to the conclusion that chronic stress and stress-related disorders play an important part in the onset of neurodegenerative disorders, and an enormous amount of research yielded valuable discoveries but has so far not led to the development of effective treatment strategies for Alzheimer’s disease. Corticotropin-releasing factor (CRF) is one of the major hormones and at the same time a neuropeptide acting in stress response. Deregulation of protein levels of CRF is involved in the pathogenesis of Alzheimer’s disease, but little is known about the precise roles of CRF and its binding protein, CRF-BP, in neurodegenerative diseases. In this review, we summarize the key evidence for and against the involvement of stress-associated modulation of the CRF system in the pathogenesis of Alzheimer’s disease and discuss how recent findings could lead to new potential treatment possibilities in Alzheimer’s disease by using CRF-BP as a therapeutic target.

Release of CRF in response to stress

Stress is a life-saving mechanism that has been shaped and refined throughout evolution¹. Acute stress leads to an increase in attention and to memory consolidation²,³. For example, anxiety is a normal reaction to stress and, if not excessive, is crucial for homeostasis. However, chronic or excessive stress leads to a decrease in performance and cognition, and hence limited adaptation to the stressor⁴,⁵. Individual kinetics and magnitude of stress response determine its outcome in terms of resilience or development of stress-related disorders⁶. This can occur in every stage of life⁷,⁸. Already before birth, stressful situations can have a major impact on the future life span of the organism as well as in newborn, young adult, and older stages of life⁹,¹⁰.

Stress response is a highly orchestrated mechanism whereby the body rapidly activates the autonomic nervous system and the hypothalamic-pituitary-adrenocortical (HPA) axis⁹,¹⁰. By activation of the HPA axis and the autonomic nervous system, an enormous number of hormones, neurotransmitters, and neuropeptides are released as adaptive reactions to restore homeostasis⁹,¹⁰. Corticotropin-releasing factor (CRF) and CRF family peptides (Fig. 1) are major regulators of stress response due to their ability to integrate physiological responses to react against a stressor, and due to their dual roles as hormones and as neuromodulators⁹,¹⁰,¹¹,¹².

As a hormone, the 41-amino acid polypeptide CRF is secreted at the onset of stress in the paraventricular nucleus of the hypothalamus¹³. CRF is delivered via the bloodstream to the anterior pituitary, where it binds to its receptors and stimulates adrenocorticotropic hormone
Glucocorticoids can exert profound modulatory effects on brain functions from early sensitive developmental stages to late adulthood. Fetal exposure to exogenous glucocorticoids or prenatal stress can lead to permanent alteration of HPA function and stress-related performance. At the adult stage, high levels of glucocorticoids and stress-related phenomena rely on transcriptional regulation and occur within time frames ranging from hours to weeks.

**Roles of CRF as a neuromodulator**

In contrast to hormones, neurotransmitters and neuromodulators exhibit fast action, allowing neurons to react to stressful situations on the synaptic level, within milliseconds to minutes. CRF acts as the principal hormone in the HPA axis, as discussed above, and triggers a number of secondary stress-related events such as secretion of the corticosteroids in the adrenal cortex. However, in addition to its action to regulate the HPA axis at the level of the pituitary, CRF is also expressed in different parts of the brain, where it can act as a neuromodulator or neurotransmitter in response to autonomic and behavioral responses. Here, CRF synergizes with corticosteroids to fine-tune stress responses in a short time frame.

CRF binds to two receptors, CRF-R1 and CRF-R2, with a higher affinity for CRF-R1 compared with its affinity for CRF-R2. CRF-R1 and CRF-R2 is modulated in vivo and in vitro by CRF-BP, a 37 kDa glycoprotein that was first detected in human plasma and structurally unrelated to CRF receptors in vertebrates. CRF-BP binds to both CRF (Ki = 0.2 nM) and UCNI (Ki = 2 nM) with sub-nanomolar affinity, which is greater than the affinity between both ligand and receptor. The affinity of CRF-BP for the CRF-R1 and CRF-R2 receptors with solid arrow lines. The weight of the solid lines will give even more detail about the affinity between both ligand and receptor. CRF displays a relatively high affinity for CRF-R1 and CRF-R2, which is greater than the affinity between both ligand and receptor. CRF-R1 and CRF-R2 are able to sequester CRF and UCN I, whereas CRF-BP exerts a low affinity for UCN II. Abbreviations; corticotropin-releasing factor (CRF), urocoritin (UCN), CRF receptor 1 (CRF-R1), CRF receptor 2 (CRF-R2), CRF-binding protein (CRF-BP), α-selective isoform of CRF-R2 (sCRF-Rα2).
### Table 1  A summary of the most common agonists and antagonists of the CRF family

| Agonist | Peptide/ nonpeptide | Peptide sequence | Binding affinity (Ki (nM)) | References |
|---------|---------------------|-----------------|-----------------------------|-------------|
| CRF-R1 h/r CRF | Peptide | SEEPPSLDLT FHLLREVLEM ARAEQLAQQA HSNRKLMEI | 1.0 (0.2–4.6) | 109/131 |
|          |          |                 |                             |             |
|          |          |                 | Alpha-helical CRF fragment 9–41 |             |
|          |          |                 | Astressin                  |             |
|          |          |                 | Antalarmin                 |             |
|          |          |                 | CP-154,526                 |             |
|          |          |                 | CP-316,311                 |             |
|          |          |                 | 0.7 (0.3–1.8)              | 103/129     |
|          |          |                 | 0.6 (0.2–5)                |             |
|          |          |                 | 0.1 (0.1–0.2)              | 109/131     |
|          |          |                 | Antisauvagine 30           |             |
|          |          |                 | 0.5 (0.3–0.7)              | 109/131     |
|          |          |                 | 0.5 (0.2–1.2)              | 109/131     |
|          |          |                 | 13.5 (9.2–19.7)            | 109/131     |
| CRF-BP CRF | Peptide | SEEPPSLDLT FHLLREVLEM ARAEQLAQQA HSNRKLMEI | 0.2          | 109/131 |
|          |          |                 | h/r CRF<sub>6-33</sub>     |             |
|          |          |                 | 0.2–5                      |             |

| Antagonist | Peptide/ nonpeptide | Peptide sequence | Binding affinity (Ki (nM)) | References |
|------------|---------------------|-----------------|-----------------------------|-------------|
| Alpha-helical CRF | Peptide | DLT FHLLREMLEM AKAEQEAQQA ALNRLLLEEA | 19 (5.5–66) | 108/130/131 |
| Astressin | Peptide | fHLLREVLEZ ARAEQLAQEA HSNRKLZEEI | 0.7 (0.3–1.8) | 103/129 |
| Antalarmin | Non-peptide | NA | 1 | 110/132 |
| CP-154,526 | Non-peptide | NA | 2.7 | 110/132 |
| CP-316,311 | Non-peptide | NA | 6.8 | 110/131 |
| 0.7 (0.3–1.8) | 103/129 |
| 0.6 (0.2–5) | 109/131 |
| 0.5 (0.1–0.2) | 109/131 |
| Antisauvagine 30 | Peptide | fHLLRKMIEI EKQEKEKQQA ANNRLLLDTI | 1.4 | 130 |
| Astressin<sub>2-B</sub> | Peptide | DLS FHLLRXXIEI EKQEKEKQQA ENKLLLDTI | 1.3 | 130 |
| 0.5 (0.2–1.2) | 109/131 |
| 13.5 (9.2–19.7) | 109/131 |
| 0.2–5 | 109/131 |

In bold, receptor activation; underlined, ECD1-binding domain; blue letter, CRF-R2 specific; double underlined, CRF-BP sequence; Ki, binding affinity.
sCRF-Ra2 is highly expressed in the olfactory bulb, cortex, midbrain, and the pituitary, and lower levels are found in the hypothalamus, pons, medulla, and spinal cord, and shows high overlap with the cellular distribution of CRF-R1. In the CNS, CRF-BP is highly expressed in the cortex, olfactory bulb, hippocampus, and amygdala, and is known to inhibit CRF actions in the HPA axis. In the brain, CRF-BP function depends on the tissue and cellular context. Here, CRF-BP and CRF exhibit limited co-expression at the cellular level. CRF-BP is localized at the CRF target sites such as the prefrontal cortex and amygdala, regions important in stress-related conditions including anxiety and addiction. Notably, there is a difference in expression of the CRF-BP between male and female mice. In females, CRF-BP expression is positively regulated by estrogen and gonadotropin-releasing hormone in pituitary cell types. This increased expression positively correlates with several conditions such as anorexia, mood disorders, and anxiety disorders, which are more prevalent in females.

In addition to its functions in stress, CRF exerts time- and dose-dependent direct actions during learning and memory formation. The exposure of neurons to acute CRF in vitro induces adaptation by spine increase and spine maturation, but exposure to high dosages of the peptide results in spine retraction and loss of synapses in the hippocampus. Opposite effects were seen in the cerebellum, where an increase of spines and dendritic complexity was observed in response to physiological concentrations of CRF in organotypic slice cultures. Clearly, effects of CRF on cellular plasticity and connectivity are highly dependent on the context, i.e., the administered dose, duration of stimulation, and cellular composition. It was further shown that chronic exposure or high levels of CRF lead to the activation of CRF-R1, and subsequently actin cytoskeleton rearrangements and atrophy of the spines and dendrites over longer time periods. This decrease in spines and in dendritic complexity, and changes in synaptic function are cellular hallmarks of cognitive impairments, characteristic, among others, for late stages of neurodegenerative disorders such as Alzheimer’s disease.

**Stress as an environmental risk factor in Alzheimer’s disease**

Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder that causes progressive cognitive impairment and structural alterations in the brain. The brains of patients with AD are characterized by the deposition of extracellular amyloid plaques consisting of β-amyloid (Aβ) peptides, the product of the proteolytic processing of the amyloid precursor protein (APP), and by abnormal hyperphosphorylation of the Tau protein, which precipitates in the form of neurofibrillary tangles inside the neurons. A hallmark of the disease is the progressive neuronal loss in the hippocampus and cortex, brain structures that are extremely important in memory formation. The most common form of AD is sporadic AD without a familial link, but genetically the disease presents as both familial and sporadic cases. Despite many years of research, whether all forms of AD have a common underlying etiology remains poorly understood. A major effort in the research field has been put into the investigation of genetic factors, although environmental factors could be similarly or even more important in the onset of the disease.

For example, in an AD mouse model, carrying a mutated form of APP, accumulation of Aβ and hyperphosphorylated Tau has been shown to occur as a result of exposure to high stress levels by acute restrained stress, chronic isolation, and social stress paradigms. A reduction in the number of mature dendritic spines in a triple-transgenic mouse model of AD (3 × Tg-AD: PS1 (M146V), APP (Swe), tau (P301L)) and increased Aβ levels due to the augmentation of amyloid-β protein precursor processing have been observed in response to short-term stress.

Exposure to stress early in life can contribute to the later development of AD. High and chronic stress levels lead to a hyper-activation of the HPA axis, which correlates with the rate of AD progression. At the same time, chronic stress and stress-dependent disorders, such as posttraumatic stress, and major depression disorders have been linked to the hyper-activation of HPA axis and are directly correlated to a dysregulation in the CRF system and AD.
but disease progression can in turn cause disruption of stress response circuits, which can exacerbate stress-like symptoms, forming a vicious cycle. On the other hand, AD is caused by a combination of different factors and not only linked to high and/or chronic stress levels.

**The link between CRF and AD**

As discussed above, the effect of chronic or high levels of stress leads to the hyperactivation of the HPA axis. Besides the elevation of glucocorticoids, clinical studies have documented the CRF dysregulation in patients with AD. Significant reduction of the CRF immunoreactivity (CRF-IR) was observed in postmortem tissue in the cerebrocortical areas and in the cerebrospinal fluid of patients with AD compared with that in control tissue. Together with the decrease in CRF-IR, increase in the concentration of the CRF receptors (CRF-Rs) in the cortex has been directly linked to AD. CRF-expressing neurons in the paraventricular nucleus of the hypothalamus show elevated levels of CRF mRNA in postmortem brain from AD patients compared with age-matched healthy controls; however, the number of CRF-expressing cells is not altered. Calcium flux measurements and neuronal death assays in culture suggested a neuroprotective role for CRF in response to Aβ toxicity in AD brain, although this hypothesis was never confirmed by in vivo studies. It has been hypothesized that CRF might stimulate non-amyloidogenic APP cleavage, exerting a beneficial effect on Aβ accumulation. In vivo animal studies identified CRF as a factor that enhances cognition and memory. Upon injection in the amygdala and the ventricles of the rat brain, CRF dose-dependently improved retention of the inhibitory avoidance response and improved acquisition of a visual discrimination task. In addition, blockade of CRF in the basolateral amygdala in rats and restoring free levels of CRF afterwards showed improved memory. Notably, these are all aspects of memory and cognition that are significantly impacted in AD patients.

In contrast to these findings, multiple studies have demonstrated that exposure to stress, along with elevated levels of CRF, provoked Aβ neuropathology. For example, in the 3 × Tg-AD mice, enhanced CRF signaling associated with short-term life stress in adults enhanced the progression of Aβ neuropathology. In parallel, infusion of CRF directly into the hippocampus increased the concentration of two major isoforms of Aβ, namely Aβ40 and Aβ42, therefore facilitating AD. Park et al. reported a link between this Aβ-enhancing potential of stress-induced CRF and γ-secretase activity as the underlying mechanism. Further, reduced CRF signaling in CRF-R1-deficient mice or treatment with the antagonist NBI-30775 (also known as R121919) both alleviated the stress-induced aggravation in Aβ pathology in a stress-like paradigm in AD mouse models. In addition to increasing Aβ concentration, CRF can also enhance Tau pathology. Enhancement of Tau phosphorylation at specific epitopes was observed in CRF-overexpressing mice and could be reversed by the specific CRF-R1 antagonist NBI-30775.

To summarize, chronic stress in combination with high CRF levels can cause stress-dependent disorders, increase the risk of AD, and can lead to other diseases. On the other hand, in neurodegenerative diseases, low CRF concentrations are observed. Chronic stress leads to HPA axis overstimulation, followed by the generation of high CRF and GRs levels in the blood, which can cause detrimental effects to neurons and their connections. These detrimental effects can lower CRF levels in the brain leading to a decrease in its neuromodulatory functions in memory and cognition.

As of today, AD remains incurable. There is a clear potential to investigate the link between CRF and AD with a focus on developing CRF-centric therapeutic approaches. Targeting CRF signaling, particularly CRF receptors, in stress disorders has been considered as a valid approach for a considerable time.

**Signaling and pharmacology of CRF receptors**

CRF-Rs belong to the family of G-protein-coupled receptors (GPCRs). These GPCRs mainly activate Gs, which will in turn increase adenylyl cyclase and stimulate enzymatic activity. Activation of the CRF-Rs, by CRF or by their other ligands, follows a two-step mechanism. First, the C-terminus of CRF binds to the N-terminus of the CRF-Rs. This first interaction causes a conformational change in the CRF-R, which stabilizes the CRF–CRF-Rs interaction, whereupon the interaction with the N-terminus of CRF initiates, and thereby triggers, cellular signaling by activating G-protein signaling. Different ligands cause different conformational changes and consequently lead to binding of different G-proteins that will each activate distinct signaling pathways. For example, in primary cells of pregnant myometrium, upon binding of UCN I with CRF-R1, there is an activation of mitogen-activated protein, which stimulates Gq for activation of the IP3-protein kinase signaling pathway; however, CRF binding does not activate the same signaling cascade. CRF-R1 peptide agonists, such as astressin (Ki = 0.7), lack the N-terminus of the CRF (Table 1) but bind with high affinity to the extracellular binding domain to prevent binding of a CRF-R agonist. The lack of the N-terminus prevents G-protein interactions and thus inhibits downstream signaling. Conversely, ligands such as α-helical CRF fragment 9–41 that lack the C-terminus (Table 1) can bind with low affinity (Ki = 19) and still will be able to activate the receptor. Non-peptide antagonists or small molecule agonists, such as NBI-
30775, antalarmin, and CRA-0450, bind almost exclusively to the juxtamembrane region, which partially inhibits CRF-R1 ligand binding by blocking the interaction of a ligand with the juxtamembrane domain, but cannot prevent the binding between the ligand and the extracellular domain of the receptor. NBI-30775, antalarmin, and CRA-0450 are allosteric inhibitors; they do not bind to the N-terminus to activate the receptor, but instead bind to the J-domain where they will cause a conformational change, leading to the inactivation of the receptor (Table 1).

To date, there are no specific non-peptide or small-molecule antagonists for CRF-R2\(^{10,108}\). CRF-R1 antagonists such as NBI-30775, pexacerfont, and CP-316,311 were the first allosteric GPCR inhibitors in clinical trials against depression and anxiety disorders. However, none of these compounds showed efficacy in advanced trials\(^{109–111}\). More recent pre-clinical discoveries present a more detailed view on the interaction between a ligand and the CRF-Rs. The observation of receptor association and dissociation revealed a significant difference between lead compounds. These differences could explain the disappointing outcome of previous clinical trials. Future trials could be improved by focusing on maximizing the receptor residence time or adjusting the dosage of antagonist to ensure CRF-R1 in the brain will remain occupied over longer periods\(^{112}\). In addition, novel technologies, such as positron emission tomography, genetic screening, and local viral CRF overexpression tools open up new opportunities to develop new compounds that will be more effective to influence CRF-R1 downstream signaling\(^{10,113}\).

**CRF-BP and treatment of AD**

A growing body of evidence suggests a prominent role of CRF-BP in the CRF system. CRF-BP regulates CRF bioavailability in the HPA axis and can restore normal levels of CRF. It is therefore tempting to consider targeting CRF-BP as a potential therapeutic route to control CRF levels, which are disrupted in AD, to improve memory and to delay AD progression.

CRF-BP is highly conserved in gene structure throughout the evolution from invertebrates to humans\(^{114}\). Studies have indicated its importance in the regulation of CRF activity\(^{39}\). CRF-BP expression is increased in the pituitary and the brain, predominantly by stress\(^{115}\). This increased expression of the CRF-BP, specifically in the HPA axis, results in lower levels of free, i.e., CRF-BP-unbound, CRF and suppresses CRF-R1 activation and downstream signaling. CRF-BP is expressed in a highly tissue-specific pattern and differs between species. Human CRF-BP is detected in the plasma, placenta, synovial fluid, amniotic fluid, liver, the pituitary, and the brain\(^{116}\). In other species, notably in rodents, CRF-BP expression is exclusively restricted to the brain and the pituitary\(^{32,39}\). These species-specific expression patterns represent an important limiting factor in behavioral and in vivo studies for evaluating the full physiological functions of the protein in rodent stress models. In the past, three different mouse models with altered CRF-BP expression were created: two transgenic mouse lines that overexpress CRF-BP and one CRF-BP knockout model\(^{117–120}\) (Table 2). Phenotypical studies showed increased anxiety in mice with a CRF-BP-null mutation\(^{117,121}\). Unfortunately, no study has so far shown changes in memory consolidation or cognition in these transgenic CRF-BP models. In the human brain, a large portion of CRF appears to be complexed with CRF-BP and therefore likely unavailable for activating CRF-Rs and downstream events\(^{122}\). The effective concentration of free CRF is not directly related to total CRF abundance. Instead, the effective concentration is a function of both CRF and CRF-BP levels\(^{116}\). Several clinical trials that investigated the inhibition of CRF by blocking its receptor CRF-R1 as a potential treatment for CRF-dependent disorders had negative outcomes, as discussed above. The clinical studies either demonstrated multiple side effects, such as in the case of compound R121919, which caused elevated liver enzymes, or reported a complete lack of efficacy, such as in the case of CP-316,311, verucerfont, and pexacerfont\(^{10,123}\). Accordingly, such drugs that directly target the binding of CRF-BP to CRF and indirectly inactivate CRF-R1 may represent attractive next-generation candidates for the treatment of stress-dependent disorders, potentially including AD.

Using the CRF-BP antagonist ligand CRF\(_6,33\). Behan et al.\(^{124}\) showed a restoration of normal brain levels of CRF in AD models. The application of CRF\(_6,33\) increased free levels of CRF and demonstrated cognition-enhancement properties in the Morris water maze paradigm of learning and memory in AD mice. This indirect approach to activate CRF-Rs does not require CRF-R agonists and is consequently unlikely to result in no characteristic side effects of CRF-R agonisms, such as disturbance in anxiety and arousal, which are characteristic to CRF-R1 and not CRF-R2\(^{124,125}\). In AD, there is no change in CRF-BP, so the total amount of hCRF does provide a readout of free levels of CRF. Therefore, releasing CRF from its binding protein would elevate the levels of available CRF in the aging brain. Consequently, CRF-BP ligands could potentially be sufficient to alleviate some of the symptoms and memory deficits in AD patients. In addition, the critical role of astrocytes in AD and other neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis is currently emerging\(^{126,127}\). Astrocytes express and release CRF-BP, and display the highest amount of membrane-bound CRF-BP. The astrocyte-associated CRF-BP reservoir
| Model                      | Molecular changes                                                                 | References |
|---------------------------|-----------------------------------------------------------------------------------|------------|
| **Genetic modifications** | **Overexpression models**                                                          |            |
| Overexpression of CRF-BP in the pituitary | Compensatory increase of CRF and arginine vasopressin in the paraventricular nucleus | 137        |
| Overexpression of CRF-BP in the brain, the pituitary, and peripheral tissue | Attenuation of ACTH secretion after lipopolysaccharide treatment | 119        |
| CRF-BP-null mutation (CRF-BP KO) | Levels of corticosterone and ACTH were unchanged | 117,121    |
| **Non-genetic modifications** | **Acute stress condition and/or removal from adrenal glands in rats (adrenalectomy)** |            |
| The acute stress condition | increased CRF-BP expression                                                        | 138        |
| Adrenalectomy condition   | decreased CRF-BP expression                                                         |            |
| Increased CRF-BP in basolateral amygdala | Decreased CRF-BP expression in the pituitary and elevated plasma corticosterone | 139        |
| The effect of acute and chronic restraint stress, specific on basolateral amygdala and dorsal hippocampus in rats | Acute stress condition: increased CRF-BP mRNA expression. Chronic stress condition: no change in CRF-BP mRNA levels in basolateral amygdala. CRF-BP mRNA levels in the hippocampus were unaltered | 140        |
| The effect of acute restraint stress in basolateral and central amygdala in rats | Increased expression in the basolateral amygdala. No change in CFR-BP expression in the central amygdala. No changes in CRF or CRF-Rs mRNA in both regions | 141        |
| Social defeat in male rats | There may be an increase in free available CRF                                        | 142        |
| **Phenotype**              | Impairment of social approach behavior. After adding CRF<sub>6-33</sub> into the bed nuclei of the stria terminalis, restored social approach |            |
might potentially play a causative role in AD and represent a therapeutic target. Astrocytes have attracted attention due to their role in disease\textsuperscript{127} and until now their roles as an important source of CRF-BP have not been broadly investigated in stress-related diseases or neurodegenerative disorders.

**Conclusions**

Stress and AD are strongly linked to each other. Ligands and receptors of the CRF system have been investigated as therapeutic targets in neuropsychiatric disorders in numerous studies and clinical trials. Interpretation of these data is not always straightforward. As discussed above, effects of CRF as neuropeptide are highly variable depending on the location, dose, and exposure time. Further, a clear distinction must be made between functions as hormone and as neuropeptide, particularly with regard to local vs. systemic and primary vs. secondary effects. Here we provide a rationale for targeting CRF-BP as an alternative approach in AD. Admittedly, there is still a shortage of mechanistic data about CRF-BP and its possible function and distribution in the brain. Two studies investigating the potential roles of CRF-BP in AD focused on its inactivating impact/effect on CRF and UCN I interactions with their receptors\textsuperscript{124,125}. In an animal model, by targeting the CRF-BP it was possible to achieve restoration of memory and learning the brain functions impaired in AD\textsuperscript{125}. These findings could lead to new treatment possibilities in AD by using CRF-BP as a therapeutic target. The aforementioned studies did not investigate any other possible roles of the binding protein, its possible brain region-specific functions, or its cellular and subcellular localization\textsuperscript{124,125}. Furthermore, one needs to consider the difference in AD prevalence between male and female subjects, and the fact that females are more susceptible to develop stress-dependent behaviors, correlating with and potentially due to the different distribution pattern of CRF-BP in the brain\textsuperscript{42,128}. Nevertheless, CRF-BP appears to be an attractive target for symptomatic treatment in AD. Inhibition of CRF-BP has the potential to boost free CRF levels, which are decreased in AD. Unlike CRF-R1 antagonists, targeting CRF-BP is unlikely to interfere with the HPA axis and to cause pertinent side effects. Clearly, more fundamental research is required prior to any progression to the clinic.

**Acknowledgements**

We thank Enigma Salta (VIB-KU Leuven) and Vasily Rybakin (REGA Institute, KU Leuven) for critical reading of the manuscript, and all members of the Goungko laboratory for discussion and comments. D.V. is supported by a Methusalem grant from KU Leuven and the Flemish Government awarded to Professor Bart De Strooper (METH/14/07).

**Author details**

1. VIB-KU Leuven Center for Brain and Disease Research, Electron Microscopy Platform, Herestraat 49, B-3000 Leuven, Belgium. 2. VIB Biomaging Core Facility, Herestraat 49, B-3000 Leuven, Belgium. 3. KU Leuven Department of Neurosciences, Leuven Brain Institute, Herestraat 49, B-3000 Leuven, Belgium.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received** 23 July 2019 **Accepted** 30 July 2019

**Published online** 22 October 2019

**References**

1. Nesse R. M., Bhatnagar S., Young E. A. in Encyclopedia of Stress p. 965–970 (Elsevier, 2007).
2. Baram, T. Z. & Joëls, M. The neuro-symphony of stress. Nat. Rev. Neurosci. 10, 459–466 (2009).
3. McEwen, B. S. & Gianaros, P. J. Stress- and allostatic-induced brain plasticity. Annu Rev Med 62, 431–445 (2010).
4. McEwen, B. S. Allostasis and allostatic load: Implications for neuropsychopharmacology. Neuropsychopharmacology 22, 108–124 (2000).
5. McEwen, B. S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873–904 (2007).
6. Bihl, K., Sharma, K. & Tremblay, M. E. Chronic stress as a risk factor for Alzheimer’s disease: roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. Neurobiol. Stress 9, 9–21 (2018).
7. Marin, M. F. et al. Chronic stress, cognitive functioning and mental health. Neurobiol. Learn Mem. 96, 583–595 (2011).
8. Charli, A., Laplante, D. P., Vaillancourt, C. & King, S. Prenatal stress and brain development. Brain Res. Rev. 65, 56–79 (2010).
9. Herman, J. P. et al. Neural regulation of endocrine and ANS responses. Clin. Auton. Res. 20, 121 (2010).
10. Deussing, J. M. & Chen, A. A. The corticotropin-releasing factor family: physiology of the stress response. Physiol. Rev. 98, 2225–2286 (2018).
11. Boorse, G. C. & Denver, R. J. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen. Comp. Endocrinol. 146, 9–18 (2006).
12. Koob, G. F. & Heinrichs, S. C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 848, 141–152 (1999).
13. Vale, W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41-residue ovine hypothalamus. Brain Res. 299, 20 (1984).
14. Junjua, M. F. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav. 38, 148–159 (2014).
15. Kapoor A., Dunn E., Kostaki A., Andrews M. H., Matthews S. G. Fetal programming of hypothalamo-pituitary-adrenal function: prenatal stress and glucocorticoids. J. Physiol. 572, 31–44 (2004).
16. Reynolds, R. M. et al. Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33, 714–720 (2010).
17. Scheuer, D. A. Regulation of the stress response in rats by central actions of glucocorticoids. Exp. Physiol. 95, 26–31 (2010).
18. de Kloet, E. R. et al. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int. 57, 1329–1336 (2000).
19. Groeneweg, F. L., Kast, H., de Kloet, E. R. & Joëls, M. Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signalling. Mol. Cell Endocrinol. 350, 299–309 (2012).
20. Maras, P. M. & Baram, T. Z. Sculpting the hippocampus from within: stress, spines, and CRH. Trends Neurosci. 35, 315–324 (2012).
21. Spiess, J., Rivier, J., Rivier, C. & Vale, W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc. Natl Acad. Sci. USA 78, 6517–6521 (1981).
22. Koob, G. F. F. Corticotropin-releasing factor and behavior. Fed. Proc. 44, 259–263 (1985).
23. Bale, T. L. & Vale, W. W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44, 525–557 (2004).
44. Gounko, N. V. et al. Corticotropin-releasing factor and urocortin regulate molecular targets. CNS. Neurol. Drug. Targets. 5, 463–479 (2006).

46. Chen, Y., Duque, C. M., Rice, C. J. & Baram, T. Z. Rapid loss of dendritic spines after stress involves derangement of spine dynamics by corticotropin-releasing hormone. J. Neurosci. 20, 2903–2911 (2000).

47. Chen, Y. et al Impairment of synaptic plasticity by the stress mediator CRH involves selective destruction of thin dendritic spines via RhoA signaling. Mol. Psychiatry 18, 485–496 (2013).

48. Annaert, W. & De Strooper, B. A cell biological perspective on Alzheimer’s disease. Annu. Rev. Cell Dev. Biol. 18, 25–51 (2002).

49. Querfurth, H. W. & LaFerla, F. M. Alzheimer’s disease: mechanism of disease. N. Engl. J. Med. 362, 329–344 (2010).

50. Weiner M. W., et al. Impact of the Alzheimer’s disease neuroimaging initiative, 2004 to 2014. Alzheimers. Dement. 11, 865–884 (2015).

51. Izquierdo, I. & Medina, J. H. Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures. Neurobiol. Learn. Mem. 68, 285–316 (1997).

52. Lavenex, P. & Banta Lavenex, P. Building hippocampal circuits to learn and remember: Insights into the development of human memory. Behav. Brain Res. 254, 8–21 (2013).

53. Goldín, T. E., Schneider, L. S. & Koo, E. H. Anti-Aβ therapies in Alzheimer’s disease: the need for a paradigm shift. Neuron 69, 203–213 (2011).

54. Retz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137–152 (2011).

55. Rothman, S. M. et al. 3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress. Neurobiol. Aging 33, 830e1–830e12 (2012).

56. Carroll, J. et al. Chronic stress exacerbates Tau pathology, neurodegeneration, and cognitive performance through a mechanism in a transgenic mouse model of tauopathy. J. Neurosci. 31, 14436–14449 (2011).

57. Dong, H. et al. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg5767) mutant mice by isolation stress. Neuroscience 127, 601–609 (2004).

58. Baglietto-Vargas, D. et al. Short-term modern life-like stress exacerbates Aβ-pathology and synaptic loss in 3xTg-AD mice. J. Neurochem. 134, 915–926 (2015).

59. Stern, Y. et al. Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 271, 1004–1010 (1994).

60. Rahia, I., Kaprio, J., Kaskenvuo, M., Rajaja, T. & Sournur, L. Environmental differences in twin pairs discordant for Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 65, 785–787 (1998).

61. Moceri, V. M. et al. Using census data and birth certificates to reconstruct the early-life socioeconomic environment and the relation to the development of Alzheimer’s disease. Epidemiology 12, 383–389 (2001).

62. Miller, D. B. & O’Callaghan, J. P. Do early-life insults contribute to the late-life development of Parkinson and Alzheimer diseases? Metabolism 57(SUPPL.2), S44–S49 (2008).

63. Pomara, N., Greenberg, W. M., Branford, M. D. & Doraiswamy, P. M. Therapeutic implications of HPA axis abnormalities in Alzheimer’s disease: review and update. Psychopharmacol. Bull. 37, 120–134 (2003).

64. Csernansky, J. G. et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry 163, 2164–2169 (2006).

65. Singh-Manoux, A. et al. Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry 74, 712–718 (2017).

66. Justice, N. J. The relationship between stress and Alzheimer’s disease. Neurol. Stress. 8, 127–133 (2018).

67. Feldman, H. et al. Behavioral symptoms in mild cognitive impairment. Neurology 62, 1199–1201 (2004).

68. Gabryelewicz, T. et al. Prevalence of major and minor depression in elderly persons with mild cognitive impairment - MADRS factor analysis. Int. J. Geriatr. Psychiatry 19, 1168–1172 (2004).

69. Pentkowski, N. S. et al. Anxiety-like behavior as an early endophenotype in the Tgfl4AD rat model of Alzheimer’s disease. Neurobiol. Aging 61, 169–176 (2018).

70. Less, G. J. et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer’s disease-related regions. Biol. Psychiatry 71, 814–821 (2012).

71. Mah, L., Binns, M. A. & Steffens, D. C. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am. J. Psychiatry 253, 466–476 (2015).

72. Lebedeva A. K., et al. MRI-based classification models in prediction of mild cognitive impairment and dementia in late-life depression. Front. Aging Neurosci. 9, 13 (2017).

73. Swaab, D. F. et al. Increased cortisol levels in aging and Alzheimer’s disease in postmortem cerebrospinal fluid. J. Neuroendocrinol. 6, 681–687 (1994).

74. De Souza E. B., Whitehouse P. J., Kuhar M. J., Price D. L., Vale W. W. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer’s disease. Nature 319, 595–598 (1986).
120. Contarino, A., Heinrichs, S. C. & Gold, L. H. Understanding corticotropin releasing factor neurobiology: contributions from mutant mice. Neuropeptides 33, 1–12 (1999).

121. Gammie, S. C., Seasholtz, A. F. & Stevenson, S. A. Deletion of corticotropin-releasing factor binding protein selectively impairs maternal, but not intermale aggression. Neuroscience 157, 502–512 (2008).

122. Jahn, O., Eckart, K., Brauns, O., Tetzal, H. & Speiss, J. The binding protein of corticotropin-releasing factor: ligand-binding site and subunit structure. Proc. Natl Acad. Sci. USA 99, 12055–12060 (2002).

123. Spierling, S. R. & Zorrilla, E. P. Don't stress about CRF: assessing the translational failures of CRF antagonists. Psychopharmacology 234, 1467–1481 (2017).

124. Behan, D. P. et al. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature 378, 284–287 (1995).

125. Behan, D. P. et al. Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer disease and control postmortem human brain. J. Neurochem. 68, 2053–2060 (1997).

126. González-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D. & Mora-Muñoz, L. Involvement of astrocytes in Alzheimer disease and strategies for maintaining cognitive health. Int. J. Fertil. Womens Med. 64, 174–185 (1999).

127. Maragakis, N. J. & Rothstein, J. D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pr. Neurol. 2, 679–689 (2006).

128. Brinlton, R. D. A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. Int. J. Fertil. Womens Med. 44, 174–185 (1999).

129. Takao, T. et al. Corticotropin-releasing factor antagonist [alpha helical CRF (9–41)] blocks central noradrenaline-induced ACTH secretion. J. Neuroendocrinol. 1, 77–78 (1989).

130. Ruhlmann, A., Bork, I., Lin, C. R., Rosenfeld, M. G. & Speiss, J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2-selective antisauvagine-30. Proc. Natl Acad. Sci. USA 95, 15264–15269 (1998).

131. Rivier, J. E. & Rivier, C. L. Corticotropin-releasing factor peptide antagonists: Design, characterization and potential clinical relevance. Front. Neuroendocrinol 35, 161–170 (2014).

132. Seymour, P. A., Schmidt, A. W. & Schulz, D. W. The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev. 9, 57–96 (2003).

133. Chaki, S. et al. Anxiolytic- and antidepressant-like profile of a new CRF receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. 485, 145–158 (2004).

134. Held, K. et al. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J. Psychiatr. Res. 38, 129–134 (2004).

135. Kunzel, H. E. et al. Treatment of depression with the CRH1-receptor antagonist R121919: endocrine changes and side effects. J. Psychiatr. Res. 37, 525–533 (2003).

136. Zorrilla, E. P., Heilig, M., de Wit, H. & Shaham, Y. Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism. Drug Alcohol Depend. 128, 175–186 (2013).

137. Burrows, H. L. et al. Excess corticotropin releasing hormone-binding protein in the hypothalamic-pituitary-adrenal axis in transgenic mice. J. Clin. Invest. 101, 1439–1447 (1998).

138. Mcclennan, S. J., Conrigh, D. N. & Seasholtz, A. F. Regulation of pituitary corticotropin-releasing hormone-binding protein messenger ribonucleic acid levels by restraint stress and adrenalectomy. Endocrinology 139, 4435–4441 (1998).

139. Timofeeva, E., Deshaies, Y., Picard, F. & Richard, D. Corticotropin-releasing hormone-binding protein in brain and pituitary of food-deprived obese (fa/fa) Zucker rats. Am. J. Physiol. Integr. Comp. Physiol. 277, R1749–R1759 (1999).

140. Lombardo, K. A. et al. Effects of acute and repeated restraint stress on corticotropin-releasing hormone binding protein mRNA in rat amygdala and dorsal hippocampus. Neurosci. Lett. 302, 81–84 (2001).

141. Herrings, R. J., Nanda, S. A., Hsu, D. T., Roseboom, P. H. & Kalin, N. H. The effects of acute stress on the regulation of central and basolateral amygdala CRF-binding protein gene expression. Mol. Brain Res. 131, 17–25 (2004).

142. Vasconcelos, M., Stein, D. J., Albrecht-Souza, L., Miczek, K. A. & de Almeida, R. M. Recovery of stress-impaired social behavior by an antagonist of the CRF binding protein, CRF6–33, in the bed nucleus of the stria terminals of male rats. Behav. Brain Res. 357–358, 104–110 (2019).